Publication | Open Access
Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy
83
Citations
27
References
2017
Year
Cancer TherapyMedicinal ChemistryHdac InhibitorsOncologyDual ParpMedicinePharmacotherapyAnti-cancer AgentCancer TreatmentPharmacologyRadiation OncologyCancer ResearchDrug Discovery
| Year | Citations | |
|---|---|---|
Page 1
Page 1